Amphastar PharmaceuticalsAMPH +7.74%83 EBITDA Margin % is 19.34% as of Mar. 2026, which is 24% below its 10-year median of 25.38. GuruFocus rates AMPH with a GF Score™ of 83/100 and a GF Value™ of $48.78 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 955 Drug Manufacturers companies, Amphastar Pharmaceuticals ranks better than 80.63% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Amphastar Pharmaceuticals EBITDA Margin % Related Terms
Amphastar Pharmaceuticals EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AMPH vs ETON, ESPR, BIOA: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amphastar Pharmaceuticals EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Amphastar Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amphastar Pharmaceuticals (AMPH) has a EBITDA Margin % of 19.34% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Amphastar Pharmaceuticals and its competitors. This is 24% below median its historical median of 25.38. Over the past decade, Amphastar Pharmaceuticals' EBITDA Margin % has ranged from 2.32 to 37.89. According to the industry distribution chart, Amphastar Pharmaceuticals ranks #185 out of 955 companies in the Drug Manufacturers industry, placing it in the top 19.4%.
Is Amphastar Pharmaceuticals' EBITDA Margin % too high?
Amphastar Pharmaceuticals' current EBITDA Margin % of 19.34% is 24% below median its 10-year median of 25.38. Over the past 10 years, this metric has ranged from a low of 2.32 to a high of 37.89. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Amphastar Pharmaceuticals' value of 19.34% is 56.1% above this industry median. Based on the distribution chart, Amphastar Pharmaceuticals ranks #185 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Amphastar Pharmaceuticals has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amphastar Pharmaceuticals' EBITDA Margin % compare to ETON and ESPR?
According to the Drug Manufacturers industry distribution chart, Amphastar Pharmaceuticals ranks #185 out of 955 companies for EBITDA Margin %. This places Amphastar Pharmaceuticals in the top 19% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.39. Amphastar Pharmaceuticals' value of 19.34% is 56.1% above this benchmark. Historically, Amphastar Pharmaceuticals' own EBITDA Margin % has ranged from 2.32 to 37.89 over the past decade. While the company's 10-year median is 25.38 vs. the industry median of 12.39, Amphastar Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amphastar Pharmaceuticals's current EBITDA Margin % of 19.34% is 56.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Amphastar Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amphastar Pharmaceuticals's current EBITDA Margin % is 19.34%, which is 24% below median its own 10-year median of 25.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amphastar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals (AMPH) is currently considered Significantly Undervalued. The stock's GF Value™ is $48.78, compared to a current price of $21.02 — trading 56.9% below its estimated fair value. The current EBITDA Margin % is 19.34%, which is 24% below median its 10-year median of 25.38 and 56.1% above the Drug Manufacturers industry median of 12.39. Amphastar Pharmaceuticals' overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Amphastar Pharmaceuticals (AMPH), the current EBITDA Margin % is 19.34% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amphastar Pharmaceuticals (AMPH) Overvalued in 2026?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals stock appears to be undervalued.
The current stock price of $21.02 is trading 56.9% below its estimated GF Value™ of $48.78.
GuruFocus considers Amphastar Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for AMPH:
EBITDA Margin %: 19.34% (24% below median its 10-year median of 25.38)
GF Value™: $48.78 vs. price of $21.02 (56.9% below fair value)
Industry Position: 56.1% above the Drug Manufacturers median (#185 of 955)
No single metric tells the full story. See the AMPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
83GF Score
Get the complete analysis for AMPH
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMPH has been successfully added to your 
